Novartis

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a ...
Novartis

Payments to Healthcare Professionals

Novartis seeks to collaborate with Healthcare Professionals and Healthcare Organizations in interest of patients. As an industry we make payments or ‘transfers of value’ to Healthcare Professionals ...
Novartis

Product portfolio

At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these treatments to as many ...
Novartis

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis

Career search

Explore opportunities with Novartis below.
Novartis

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...
Novartis

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence

Novartis Chief Digital Officer, Bertrand Bodson and Microsoft Healthcare Corporate Vice President, Peter Lee also discussed the potential of data science and AI during a recent visit to Novartis ...
Novartis

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled ...

Asthma affects an estimated 358 million people worldwide and can cause a significant personal, health and financial burden when not adequately controlled 3,4 “Novartis is working to reimagine medicine ...
Novartis

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction ...
Novartis

Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy

Divested assets to include Xiidra ®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface pain Deal consistent with Novartis focused strategy of ...